array:24 [ "pii" => "S2387020620301868" "issn" => "23870206" "doi" => "10.1016/j.medcle.2019.04.049" "estado" => "S300" "fechaPublicacion" => "2020-06-26" "aid" => "4887" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2019" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2020;154:524-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0025775319304051" "issn" => "00257753" "doi" => "10.1016/j.medcli.2019.04.029" "estado" => "S300" "fechaPublicacion" => "2020-06-26" "aid" => "4887" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2020;154:524-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>" "titulo" => "Neoplasia de células dendríticas blásticas plasmacitoides. Estudio de tres casos" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "524" "paginaFinal" => "525" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Blastic plasmacytoid dendritic cell neoplasm. A study of three cases" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marta Sitges, Susana Vives, Josep-Maria Ribera" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Marta" "apellidos" => "Sitges" ] 1 => array:2 [ "nombre" => "Susana" "apellidos" => "Vives" ] 2 => array:2 [ "nombre" => "Josep-Maria" "apellidos" => "Ribera" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020620301868" "doi" => "10.1016/j.medcle.2019.04.049" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620301868?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775319304051?idApp=UINPBA00004N" "url" => "/00257753/0000015400000012/v1_202006120627/S0025775319304051/v1_202006120627/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2387020620301947" "issn" => "23870206" "doi" => "10.1016/j.medcle.2019.06.031" "estado" => "S300" "fechaPublicacion" => "2020-06-26" "aid" => "4984" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Med Clin. 2020;154:526" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Image in medicine</span>" "titulo" => "Acute otitis media with facial nerve palsy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "526" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Otitis media aguda con parálisis del nervio facial" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 920 "Ancho" => 905 "Tamanyo" => 120141 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Kalaiarasi Raja, Satvinder Singh Bakshi" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Kalaiarasi" "apellidos" => "Raja" ] 1 => array:2 [ "nombre" => "Satvinder Singh" "apellidos" => "Bakshi" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620301947?idApp=UINPBA00004N" "url" => "/23870206/0000015400000012/v1_202006190827/S2387020620301947/v1_202006190827/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S238702062030187X" "issn" => "23870206" "doi" => "10.1016/j.medcle.2019.04.050" "estado" => "S300" "fechaPublicacion" => "2020-06-26" "aid" => "4888" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2020;154:524" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Mesenteric ischemia due to acrylic embolism after performing a percutaneous vertebroplasty" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "524" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Isquemia mesentérica por embolia acrílica tras la realización de una vertebroplastia percutánea" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Francisco Epelde, Sandra Pérez" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Francisco" "apellidos" => "Epelde" ] 1 => array:2 [ "nombre" => "Sandra" "apellidos" => "Pérez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775319304063" "doi" => "10.1016/j.medcli.2019.04.030" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775319304063?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S238702062030187X?idApp=UINPBA00004N" "url" => "/23870206/0000015400000012/v1_202006190827/S238702062030187X/v1_202006190827/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Blastic plasmacytoid dendritic cell neoplasm. A study of three cases" "tieneTextoCompleto" => true "saludo" => "<span class="elsevierStyleItalic">Dear Editor</span>," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "524" "paginaFinal" => "525" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Marta Sitges, Susana Vives, Josep-María Ribera" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Marta" "apellidos" => "Sitges" "email" => array:1 [ 0 => "martasitges90@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Susana" "apellidos" => "Vives" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Josep-María" "apellidos" => "Ribera" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Hematología Clínica, ICO-Badalona, Hospital Germans Trias i Pujol, Badalona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Instituto de Investigación contra la Leucemia Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Neoplasia de células dendríticas blásticas plasmacitoides. Estudio de tres casos" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive hemopathy recognized in the 2008 WHO classification.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1,2</span></a> It was first described in 1990 and since then has undergone multiple nomenclature changes.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> Represents 0.44% of malignant blood diseases<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> predominantly affecting men in the sixth decade, although some cases have also been described in children. Its diagnosis can be complex and lacks standardized treatment due to its low incidence and the lack of prospective studies. We report three cases diagnosed in one centre who received individualized treatment according to age and functional status.</p><p id="par0010" class="elsevierStylePara elsevierViewall">The first patient is a 29-year-old man with cutaneous and central nervous system involvement who received treatment according to the Hyper-CVAD regimen (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>) with which he achieved complete response (CR). Subsequently, he received an allogeneic hematopoietic stem-cell transplantation (AHSCT) after which he remained in CR. The second patient is a 66-year-old man with hepatomegaly, lymphadenopathy, and blasts in peripheral blood, who was treated with a protocol for acute lymphoblastic leukaemia (ALL) for elderly patients (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>) after which he achieved CR. He received an AHSCT and died 3 months later due to septic shock. The third patient is a 79-year-old woman with a several-month history of skin lesions and detection of blasts in peripheral blood 4 months later. She received treatment according to the R-CHOP regimen (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), after which she died due to disease progression.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">The treatment of BPDCN is based on retrospective studies with a limited number of cases. Therapeutic regimens for acute myeloblastic leukaemia and ALL are the most widely used (as in cases 1 and 2), with a high rate of complete responses (41–100%).<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> ALL regimens appear to be superior, but the available evidence is weak. Non-Hodgkin’ lymphoma regimens have also been used, which, even though they appear to be less effective, may be the choice in more fragile patients (as occurred in the third patient). However, the response to treatment is usually short-lived (6–9 months) with a high relapse rate (33–100%), which determines a short overall survival (OS) of 12–16 months.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> The prognosis in relapse is very poor and effective therapeutic options are not available. For this reason, consolidation with AHSCT in the first CR is recommended (as was done in the first two patients in this series). In a recent multicenter study, patients who received an AHSCT had a 58% probability of OS at 3 years.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> In addition, differences in OS were observed between patients transplanted in the first CR or not (3-year OS of 74% vs. 0%).<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> Autologous transplantation has also been used and, although it seems to have worse outcomes, it could be considered in patients with comorbidities that prevent performing an AHSCT.</p><p id="par0020" class="elsevierStylePara elsevierViewall">However, it should be taken into account that BPDCN is often diagnosed in elderly patients with comorbidities, who are not candidates for AHSCT or intensive therapy (as occurred in the third patient). Radiotherapy can be effective in localized disease, but relapse is very common and is therefore reserved for elderly patients who are not candidates for intensive treatment. Systemic treatment is recommended in the rest of the patients. New therapies are being developed to improve first-line and relapse outcomes. SL-401, a recombinant interleukin 3α conjugated to diphtheria toxin has shown a significant rate of overall responses, albeit short-lived, in a phase 1/2 study.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> Other drugs such as venetoclax, bortezomib, or hypomethylating agents are also being studied.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">2,3,5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">In conclusion, the available evidence to standardize the treatment of BPDCN is scarce. Various therapeutic options are available, depending on the clinical context, and AHSCT could play an important role in improving long-term results. However, more effective first-line therapeutic strategies are needed to improve treatment outcomes, especially for patients who are not candidates for intensive therapy.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding</span><p id="par0030" class="elsevierStylePara elsevierViewall">Partially financed with grants <span class="elsevierStyleGrantNumber" refid="gs1">RD12/0036/0029</span> (<span class="elsevierStyleGrantSponsor" id="gs1">Telematic Network for Cooperative Cancer Research, Spain</span>), <span class="elsevierStyleGrantNumber" refid="gs2">PI14/01971FIS</span> (<span class="elsevierStyleGrantSponsor" id="gs2">Instituto Carlos III, Spain</span>), and SGR 288 (GRC) of the <span class="elsevierStyleGrantSponsor" id="gs3">CERCA program of the Generalitat de Catalunya (Spain)</span>.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Sitges M, Vives S, Ribera J-M. Neoplasia de células dendríticas blásticas plasmacitoides. Estudio de tres casos. Med Clin (Barc). 2020;154:524–525.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">AHSCT: allogeneic hematopoietic stem-cell transplantation; CHOP: prednisone 80<span class="elsevierStyleHsp" style=""></span>mg day 1, vincristine 1.2<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> day 1, adriamycin 25<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> day 1, cyclophosphamide 750<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> day 1, prednisone 100<span class="elsevierStyleHsp" style=""></span>mg days 2–5; Cy-ICT: cyclophosphamide 60<span class="elsevierStyleHsp" style=""></span>mg/kg days -7 and -8, total body irradiation 9<span class="elsevierStyleHsp" style=""></span>Gy in 3 days; Flu/Bu/Thiotepa: Thiotepa 5<span class="elsevierStyleHsp" style=""></span>mg/kg/day (days -7 to -6), fludarabine 50<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2/</span>day (days -5 to -3), busulfan 3.2<span class="elsevierStyleHsp" style=""></span>mg/kg/day (days -4 to -3); Hyper-CVAD: dexamethasone 40<span class="elsevierStyleHsp" style=""></span>mg days 1–4 and 11–14, cyclophosphamide 300<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> days 1–3, adriamycin 50<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> day 4 and vincristine 2<span class="elsevierStyleHsp" style=""></span>mg days 4 and 11, alternated with methotrexate 1000<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> day 1 and cytarabine 3000<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> day 2; PETHEMA ALL Old-2007: induction: dexamethasone 10<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> days 1–2 and 8–11, idarubicin 10<span class="elsevierStyleHsp" style=""></span>mg days 1–2 and 8–9, vincristine 1<span class="elsevierStyleHsp" style=""></span>mg days 1 and 8, cyclophosphamide 300<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> days 15–17, cytarabine 60<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> days 16–19 and 23–26. Maintenance: methotrexate 1000<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> day 1, <span class="elsevierStyleSmallCaps">l</span>-asparaginase 10,000<span class="elsevierStyleHsp" style=""></span>IU/m<span class="elsevierStyleSup">2</span> day 2 alternated with cytarabine 1000<span class="elsevierStyleHsp" style=""></span>mg/m<span class="elsevierStyleSup">2</span> days 1, 3 and 5. PB: peripheral blood.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Case 1 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Case 2 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Case 3 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sex \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">66 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">79 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Leukocytes (×10<span class="elsevierStyleSup">9</span>/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Haemoglobin (g/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">154 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">147 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">124 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Blasts PB (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyper-CVAD x2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PETHEMA ALL Old-2007 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CHOP \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Response \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Complete response \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Complete response \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not rated \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AHSCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Follow-up \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">68 months, alive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 months, death from septic shock \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 months, death due to disease progression \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2319311.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Summary of three clinical cases with plasmacytoid dendritic cell neoplasm.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blastic plasmacytoid dendritic cell neoplasm" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F. Facchetti" 1 => "T. Petrella" 2 => "S.A. Pileri" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:5 [ "editores" => "S.H.Swerdlow, E.Campo, N.Lee" "titulo" => "WHO classification of tumours of haematopoietic and lymphoid tissues" "paginaInicial" => "174" "paginaFinal" => "175" "serieFecha" => "2017" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L. Pagano" 1 => "C. Valentini" 2 => "S. Grammatico" 3 => "A. Pulsoni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjh.14146" "Revista" => array:6 [ "tituloSerie" => "Br J Haematol" "fecha" => "2016" "volumen" => "174" "paginaInicial" => "188" "paginaFinal" => "202" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27264021" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Haematopoeitic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Kharfan-Dabaja" 1 => "M. Al Malki" 2 => "U. Deotare" 3 => "R.V. Raj" 4 => "N. El-Jurdi" 5 => "N. Majhail" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjh.14954" "Revista" => array:6 [ "tituloSerie" => "Br J Haematol" "fecha" => "2017" "volumen" => "179" "paginaInicial" => "781" "paginaFinal" => "789" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28980314" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.E. Frankel" 1 => "J.H. Woo" 2 => "C. Ahn" 3 => "N. Pemmaraju" 4 => "B.C. Medeiros" 5 => "H.E. Carraway" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2014-04-566737" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2014" "volumen" => "124" "paginaInicial" => "385" "paginaFinal" => "392" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24859366" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Montero" 1 => "J. Stephansky" 2 => "T. Cai" 3 => "G.K. Griffin" 4 => "L. Cabal-Hierro" 5 => "K. Togami" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/2159-8290.CD-16-0999" "Revista" => array:6 [ "tituloSerie" => "Cancer Discov" "fecha" => "2016" "volumen" => "7" "paginaInicial" => "156" "paginaFinal" => "164" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27986708" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000015400000012/v1_202006190827/S2387020620301868/v1_202006190827/en/main.assets" "Apartado" => array:4 [ "identificador" => "43309" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000015400000012/v1_202006190827/S2387020620301868/v1_202006190827/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020620301868?idApp=UINPBA00004N" ]
Journal Information
Vol. 154. Issue 12.
Pages 524-525 (June 2020)
Share
Download PDF
More article options
Vol. 154. Issue 12.
Pages 524-525 (June 2020)
Letter to the Editor
Blastic plasmacytoid dendritic cell neoplasm. A study of three cases
Neoplasia de células dendríticas blásticas plasmacitoides. Estudio de tres casos
Visits
4
This item has received
Article information
These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscribe
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail